Skip to content

Certification of Good Manufacturing and Distribution Practice for Medicines: PERATURAN BPOM 16/2026

Share
Regulatory digest Published 20 November 2026 Machine-drafted

Regulation of the Food and Drug Supervisory Agency (BPOM) Number 16 of 2026 sets out how BPOM certifies Good Manufacturing Practice for Medicines (CPOB) and Good Distribution Practice for Medicines (CDOB). The Head of the Agency, Taruna Ikrar, signed it in Jakarta on 3 September 2026. The held text runs to 99 articles in seven chapters: general provisions, CPOB certification, CDOB certification, force majeure, administrative sanctions, transitional provisions and closing provisions. It replaces separate certification rules from 2011 and 2017. Its subject sits next to BPOM's rules on medicine handling at pharmacy service facilities.

Key Provisions

Who must hold a CPOB certificate. Under Pasal 2, business actors must apply the CPOB standard to ensure the safety, efficacy and quality of medicines and medicinal ingredients. They are pharmaceutical industries, institutions, and facilities that manufacture medicines or medicinal ingredients, including medicines made for clinical trials; institutions and facilities may be government bodies. Compliance is proven by a CPOB certificate issued by the Head of the Agency. For clinical-trial medicines, a facility-use approval issued by BPOM may also serve as proof.

Scope of each certificate. Pasal 3 grants a CPOB certificate for each building unit, according to the dosage form and the manufacturing process carried out at all or some stages. One manufacturing process for one dosage form spread over several buildings receives one certificate. Medicinal ingredients receive a certificate for each production line, biological products for each line of the manufacturing process, and radiopharmaceuticals according to the route of administration or route of manufacturing and the radionuclide used.

Applications. Pasal 4 requires applications to be filed electronically with the Head of the Agency through the online single submission system, integrated with BPOM's CPOB certification website. Applicants outside the business-actor criteria of the risk-based licensing rules apply through the BPOM website. Pasal 6 lists the applications a registered business actor may file: new certification, changes to and extension of a certificate, and approval, change or extension of a warehouse outside the factory site.

Who must hold a CDOB certificate. Under Pasal 62, business actors and pharmaceutical management facilities that procure, store and distribute medicines, or that run electronic systems for medicine distribution, must apply the CDOB standard, proven by a CDOB certificate. The business actors are pharmaceutical wholesalers and their branches, medicinal-ingredient wholesalers and their branches, and electronic system and e-commerce operators. Pasal 63 requires the certificate before operations begin. Pasal 64 grants it by product category, such as cold-chain products, narcotics, psychotropics and prescription medicines, and by activity.

Force Majeure and Sanctions

Pasal 94 allows certification to proceed manually, or to be postponed for three months, when an electronic system failure, riot, fire or natural disaster occurs. If the application still cannot be completed, it is rejected. Pasal 95 lists the administrative sanctions the Head of the Agency may impose for breaches of named provisions, including Pasal 63(1) and (2): warning, strong warning, temporary suspension of activities, temporary closure of access to licensing applications, freezing of a certificate, and revocation of a certificate. Pasal 96 refers the procedure to the BPOM regulation on follow-up to supervision results.

Transitional Provisions

Under Pasal 97, applications filed before the regulation took effect are processed under the 2011 and 2017 rules, and existing CPOB and CDOB certificates stay valid until they expire. Off-site warehouse approvals with no validity period are revoked, and holders must apply for a new approval within six months. Approvals for off-site secondary packaging facilities lapse one year after promulgation. National and provincial pharmaceutical management facilities must hold a CDOB certificate within five years of promulgation, and district and city facilities within seven years.

Revocation and Entry into Force

Pasal 98 revokes BPOM Head Regulation Number HK.04.1.33.12.11.09937 of 2011 on CPOB certification and BPOM Head Regulation Number 25 of 2017 on CDOB certification. It also revokes BPOM Regulation Number 20 of 2025 on CDOB standards, to the extent it governs the application of CDOB by pharmaceutical management facilities as proven by a CDOB certificate. Under Pasal 99, the regulation takes effect on the date it is promulgated.

Checked against the official text of PERATURAN_BPOM 16/2026 on 18 November 2026. This is not legal advice; report corrections to contact@crpg.id.


Disclaimer

This article was AI-generated under an experimental legal-AI application. It may contain errors, inaccuracies, or hallucinations. The content is provided for informational purposes only and should not be relied upon as legal advice or authoritative interpretation of regulations.

We accept no liability whatsoever for any decisions made based on this article. Readers are strongly advised to:

  • Consult the official regulation text from government sources
  • Seek professional legal counsel for specific matters
  • Verify all information independently

This experimental AI application is designed to improve access to regulatory information, but accuracy cannot be guaranteed.